Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer
PHASE2CompletedINTERVENTIONAL
Enrollment
29
Participants
Timeline
Start Date
October 31, 2007
Primary Completion Date
April 30, 2010
Study Completion Date
March 31, 2012
Conditions
Primary Peritoneal Cavity CancerRecurrent Ovarian Epithelial CancerStage III Ovarian Epithelial CancerStage IV Ovarian Epithelial Cancer
Interventions
DRUG
gemcitabine hydrochloride
Given IV
DRUG
tanespimycin
Given IV
Trial Locations (1)
55905
Mayo Clinic, Rochester
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00093496 - Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer | Biotech Hunter | Biotech Hunter